Sulfuric Acid

Sulfuric Acid

SCHEMBL2379847

CCOC(=N)N.O=S(=O)([O-])O.[H+]

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CYP51cyp51Acyp51c

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.41
KDM4E B2RXH2 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
BLM P54132 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
TSHR P16473 1/20 0.33
LMNA P02545 2/20 0.32
HSD17B10 Q99714 1/20 0.32
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
GAA P10253 2/20 0.31
MGAM O43451 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
SOAT1 P35610 1/20 0.31
CA12 O43570 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL2379844 0.89 ALOX15 (0.46) ALOX15KDM4ECYP2D6CYP2C19BLM
Hydrochloric Acid SCHEMBL16323029 0.81
SCHEMBL643463 0.81
Bromide SCHEMBL23123928 0.78
Hydrochloric Acid SCHEMBL2377983 0.78
Sulfuric Acid SCHEMBL637684 0.77 KDM4E (0.40) KDM4ECYP2D6CYP2C19BLMNPSR1
Acetic Acid SCHEMBL31317504 0.75 ALOX15 (0.52) ALOX15KDM4ECYP2D6ALDH1A1KMT2A
Sulfuric Acid SCHEMBL5693208 0.73 KDM4E (0.37) KDM4ECYP2D6CYP2C19BLMNPSR1
Sulfuric Acid SCHEMBL21827141 0.72
SCHEMBL1891967 0.72 ALOX15 (0.42) ALOX15CYP2D6CYP2C19ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250235390-A1 Composition and Process for Treating a Disorder in the Oral Cavity of a Mammal SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2025-07-24 US disclosed
EP-3534867-B1 MEDICAL COMPOSITION CONTAINING GUANIDINYL-CONTAINING POLYMER(S) AND CARRAGEENANE(S) SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2025-06-04 EP disclosed
EP-3534866-B1 METHOD OF DENTAL RETRACTION WITH COMPOSITION WITH GUANIDINYL-CONTAINING POLYMER SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2025-05-28 EP disclosed
US-12295369-B2 Articles containing a crosslinked guanidinyl-containing polymer and uses thereof SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2025-05-13 US disclosed
US-20250082440-A1 Composition for Isolating Tissue SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2025-03-13 US disclosed
EP-4419062-A1 COMPOSITION AND PROCESS FOR TREATING A DISORDER IN THE ORAL CAVITY OF A MAMMAL Solventum Intellectual Properties Company (US) 2024-08-28 EP disclosed
EP-4380494-A1 COMPOSITION FOR ISOLATING TISSUE Solventum Intellectual Properties Company (US) 2024-06-12 EP disclosed
US-20240024205-A1 DENTAL RETRACTION COMPOSITION SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2024-01-25 US disclosed
US-11827864-B2 Wipe with a guanidinyl-containing polymer 3M INNOVATIVE PROPERTIES COMPANY (US) 2023-11-28 US disclosed
EP-4259035-A1 DENTAL RETRACTION COMPOSITION 3M Innovative Properties Company (US) 2023-10-18 EP disclosed
WO-2014204763-A1 PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-12-24 WO disclosed
WO-2014088807-A1 GUANIDINE-FUNCTIONALIZED PARTICLES AND METHODS OF MAKING AND USING 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-06-12 WO disclosed
US-20130224825-A1 LIGAND FUNCTIONALIZED POLYMERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-08-29 US disclosed
US-20130217032-A1 LIGAND FUNCTIONALIZED POLYMERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-08-22 US disclosed
US-8435776-B2 Ligand functionalized polymers 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-05-07 US disclosed
EP-2542889-A1 LIGAND GUANIDINYL FUNCTIONALIZED POLYMERS 3M Innovative Properties Company (US) 2013-01-09 EP disclosed
WO-2011109151-A1 LIGAND GUANIDINYL FUNCTIONALIZED POLYMERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-09-09 WO disclosed
US-20110217752-A1 LIGAND FUNCTIONALIZED POLYMERS 3M INNOVATIVE PROPERTIES COMPANY 2011-09-08 US disclosed
US-5552546-A Process for the preparation of 2-ethoxy-4,6-dihydroxypyrimidine DOWELANCO (US) 1996-09-03 US disclosed
US-5463055-A Reacting O-ethylisourea (or salt) with an alcoholate and/or a malonic acid dialkyl ester derivative, then acidification, desalting SKW TROSTBERG AKTIENGESELLSCHAFT (DE) 1995-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12295369-B2 Articles containing a crosslinked guanidinyl-containing polymer and uses thereof C5, YTHDC1, PRMT1 ALOX15 2868/4885KDM4E 960/4885CYP2D6 2542/4885
US-20240024205-A1 DENTAL RETRACTION COMPOSITION GK, GANC, JMJD1C ALOX15 3106/4885KDM4E 72/4885CYP2D6 4648/4885
US-20250235390-A1 Composition and Process for Treating a Disorder in the Oral Cavity of a Mammal GSDMD, PIGS, GANC ALOX15 277/4885KDM4E 3077/4885CYP2D6 4639/4885
US-11827864-B2 Wipe with a guanidinyl-containing polymer GNPDA1, GDA, PGLS ALOX15 4735/4885KDM4E 546/4885CYP2D6 3266/4885
US-20130224825-A1 LIGAND FUNCTIONALIZED POLYMERS SELPLG, CD69, SIGLEC7 ALOX15 2901/4885KDM4E 4413/4885CYP2D6 1595/4885
US-20110217752-A1 LIGAND FUNCTIONALIZED POLYMERS SELPLG, CD69, SIGLEC7 ALOX15 2901/4885KDM4E 4413/4885CYP2D6 1595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.